BioSpace News Archive

CadheRx Therapeutics, launched by Avalon Ventures and GSK, is discovering and developing therapeutic antibodies targeting soluble E-cadherin (sEcad) for the treatment of solid tumours including epithelial cancers.

Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers.

Biocon Limited, publicly listed in 2004, is India’s largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries.

We are pioneers in surgical navigation and precision healthcare, empowering physicians with safe, real-time, imaging solutions that improve outcomes, lower costs, and reduce radiation exposure for both patients and caregivers in minimally invasive endovascular procedures.

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain.

Arbor Bio is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics.

Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology.

The mission of Shepherd is to cure rare cancers. Founded by a rare cancer patient, Shepherd is a biotechnology company relentlessly focused on using deep disease understanding, development expertise, and an unwavering commitment to save people dying of neglected rare cancers.